ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

6 links0 made here, not in the record6 judgments1 judge (the rules as one: Rule based)1 record change seen
Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07235202A Study of MR001 CombinedWith Chemotherapy inPatients With LocallyAdvanced or MetastaticPancreatic DuctalAdenocarcinoma (PDAC) AfterFirst-line TherapyShenzhen Majory Biotechnology Phase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Version of 2026-11-06CONDITIONSPancreatic Ductal Adenocarc…No longer in the registry's filing›Nov 14 · Rule based · Not readNot readDRUGSINT027232Entry “MR001”, read by our name rule›As of now · Rule based · BackgroundBackgroundIrinotecan sucrosofateEntry “Irinotecan Liposome Injection …›As of now · Rule based · BackgroundBackgroundFluorouracilEntry “Irinotecan Liposome Injection …›As of now · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Nab-paclitaxel”, read by our n…›As of now · Rule based · BackgroundBackgroundGemcitabineEntry “Gemcitabine (GEM)”, read by ou…›As of now · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pancreatic Ductal Adenocarcinoma (PDAC)

From the registry record1 judgment on this link
Kind of condition link, from the registry to what was judged
RegistryPancreatic Ductal Adenocarcinoma (PDAC), once filedthe registry files the study under it
→judged→
On the pageNo longer linkedthe registry no longer files it here

All judgments on this study

WhenLinkJudgeDecisionState
Nov 6The record itselfClinicalTrials.gov recordVersion of 2026-11-06Record change
Nov 14Pancreatic Ductal Adenocarcinoma (PDAC)Rule based · condition-kind ruleNot readCurrent
As of nowINT027232Rule based · role ruleBackgroundCurrent
As of nowIrinotecan sucrosofateRule based · role ruleBackgroundCurrent
As of nowFluorouracilRule based · role ruleBackgroundCurrent
As of nowAlbumin-Bound PaclitaxelRule based · role ruleBackgroundCurrent
As of nowGemcitabineRule based · role ruleBackgroundCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.